Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

— CRC009  

Official title:

CMAB009 Plus Irinotecan Versus Irinotecan-only as Second-line Treatment After Fluoropyrimidine and Oxaliplatin Failure in KRAS Wild-type Metastatic Colorectal Cancer Patients: Prospective, Open-label, Randomized, Phase II/III Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01550055
• Other study ID #: CMAB009mCRC?/?
• Secondary ID: CMAB009
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: May 31, 2009
• Est. completion date: July 23, 2015

Study information

• Verified date: April 2019
• Source: Shanghai Zhangjiang Biotechnology Limited Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients

Description:

CMAB009 is a recombinant, human/mouse chimeric monoclonal antibody (mAb) that binds specifically to the extracellular domain of EGFR. It is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and k light chain constant regions and it is expressed by Chinese hamster ovary cells. It has the same amino acid sequence as cetuximab (C225, Erbitux®) , but it has slightly different abilities for glycosylation and other post-translational modifications, and it is developed by Shanghai Zhangjiang Biotechnology Limited Company and produced by Biomabs. Phase I study results suggest that CMAB009 showed well-tolerated safety profile and primary efficacy. This multicenter, open-label study was to determine whether adding CMAB009 to irinotecan increased the response rate and prolongs survival in patients with KRAS wild-type metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 512
• Est. completion date: July 23, 2015
• Est. primary completion date: December 23, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• histologically confirmed metastatic colorectal adenocarcinoma

• KRAS wild-type tumors, EGFR-expressing or EGFR-nonexpressing by immunohistochemistry;

• has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diametre by physical examination or other iconography

• ECOG performance status 0 to 1

• Failure (disease progression/discontinuation due to toxicity) of fluoropyrimidine and oxaliplatin treatment,stop at least one month thereafter, irinotecan-naïve

Exclusion Criteria:

• Previous irinotecan or anti-EGFR therapies

• hematologic function: hemoglobin, less than 90g per liter; neutrophil count, less than 1500 per cubic millimeter; and platelet count, less than 100,000 per cubic millimeter

• liver function: bilirubin, more than 1.0 times the upper limit of normal; aspartate aminotransferase and alanine aminotransferase, more than 5.0 times and 2.5 times the upper limit of normal with hepatic metastasis or not

• Renal function: serum creatinine, more than 1.5 times the upper limit of normal

• Patients with symptomatic central nervous system metastases

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• CMAB009 plus Irinotecan
Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
• Irinotecan-only and sequential-CMAB009
First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Zhangjiang Biotechnology Limited Company	Shanghai Biomabs Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate	Tumor response was evaluated every 6 weeks and confirmed at least 4 weeks later	Time to progression, assessed up to two years
Secondary	Progression-free Survival	The study was designed to evaluate the PFS as second end point, progression-free survival is defined as the period from date of randomization to date of disease progression	Time to progression, assessed up to two years